Free Trial

Longboard Pharmaceuticals (LBPH) Stock Forecast & Price Target

$35.50
+1.90 (+5.65%)
(As of 07/24/2024 ET)

Longboard Pharmaceuticals - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Based on 8 Wall Street analysts who have issued ratings for Longboard Pharmaceuticals in the last 12 months, the stock has a consensus rating of "Buy." Out of the 8 analysts, 8 have given a buy rating for LBPH.

Consensus Price Target

$54.63
53.87% Upside
High Forecast$90.00
Average Forecast$54.63
Low Forecast$32.00

According to the 8 analysts' twelve-month price targets for Longboard Pharmaceuticals, the average price target is $54.63. The highest price target for LBPH is $90.00, while the lowest price target for LBPH is $32.00. The average price target represents a forecasted upside of 53.87% from the current price of $35.50.

TypeCurrent Forecast
7/25/23 to 7/24/24
1 Month Ago
6/25/23 to 6/24/24
3 Months Ago
4/26/23 to 4/25/24
1 Year Ago
7/25/22 to 7/25/23
Consensus Rating
Buy
Buy
Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
8 Buy rating(s)
8 Buy rating(s)
6 Buy rating(s)
5 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$54.63$44.38$39.50$17.40
Forecasted Upside53.87% Upside121.43% Upside127.82% Upside190.47% Upside
Get Longboard Pharmaceuticals Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for LBPH and its competitors with MarketBeat's FREE daily newsletter.

LBPH Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

LBPH Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Longboard Pharmaceuticals Stock vs. The Competition

TypeLongboard PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.72
2.51
Consensus RatingBuyModerate BuyModerate Buy
Predicted Upside53.87% Upside3,254.43% Upside10.61% Upside
News Sentiment RatingPositive News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
7/11/2024Robert W. Baird
2 of 5 stars
 Boost TargetOutperform ➝ Outperform$36.00 ➝ $60.00+62.12%
7/2/2024Citigroup
3 of 5 stars
 Boost TargetBuy ➝ Buy$40.00 ➝ $45.00+42.63%
7/2/2024Evercore ISI
2 of 5 stars
 Boost TargetOutperform ➝ Outperform$57.00 ➝ $80.00+150.86%
7/1/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight$60.00 ➝ $90.00+208.32%
6/11/2024B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$30.00 ➝ $36.00+90.58%
6/11/2024HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingBuy ➝ Buy$60.00 ➝ $60.00+230.76%
5/3/2024Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$32.00 ➝ $34.00+44.93%
1/2/2024Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$16.00 ➝ $32.00+72.51%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 09:42 PM ET.

LBPH Forecast - Frequently Asked Questions

What is Longboard Pharmaceuticals' forecast for 2024?

According to the research reports of 8 Wall Street equities research analysts, the average twelve-month stock price forecast for Longboard Pharmaceuticals is $54.63, with a high forecast of $90.00 and a low forecast of $32.00.

Should I buy or sell Longboard Pharmaceuticals stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Longboard Pharmaceuticals in the last year. There are currently 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LBPH shares.

Does Longboard Pharmaceuticals's stock price have much upside?

According to analysts, Longboard Pharmaceuticals's stock has a predicted upside of 109.41% based on their 12-month stock forecasts.

What analysts cover Longboard Pharmaceuticals?

Longboard Pharmaceuticals has been rated by research analysts at B. Riley, Cantor Fitzgerald, Citigroup, Evercore ISI, HC Wainwright, Robert W. Baird, and Wedbush in the past 90 days.

Do Wall Street analysts like Longboard Pharmaceuticals more than its competitors?

Analysts like Longboard Pharmaceuticals more than other "medical" companies. The consensus rating for Longboard Pharmaceuticals is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how LBPH compares to other companies.


This page (NASDAQ:LBPH) was last updated on 7/24/2024 by MarketBeat.com Staff

From Our Partners